New Institutional Equity Positions
Cullen Capital Discloses Significant New Positions Across Pharmaceutical, Consumer, and Industrial Sectors
Anonymous
Key Points
1
About 98.28% of Axalta Coating Systems stock is currently owned by institutional investors, underscoring a highly institutionalized base alongside Cullen Capital’s new stake.
2
Mizuho raised its price target on Axalta Coating Systems in coverage following Cullen Capital’s Q2 activity, indicating renewed analyst attention on the name.
3
Clorox declared a quarterly dividend of $1.25 per share, with a record date of Aug. 12 and payment date of Aug. 28, as part of ongoing earnings-related disclosures alongside the new stake.
4
Bristol Myers Squibb stock is reported as 76.41% owned by hedge funds and institutional investors, highlighting broad institutional interest around Cullen Capital’s new stake.
5
Veralto CEO Jennifer Honeycutt sold 7,097 shares on July 29 at an average price of $101.52, while the CEO still holds a substantial position after the sale.
Cullen Capital Management LLC expanded its portfolio in the second quarter with new stakes across multiple large-cap companies. The investment firm acquired 97,586 shares of Axalta Coating Systems valued at roughly $3.34 million, plus positions in Bristol Myers Squibb ($65.25 million), Clorox ($1.02 million), Copa Holdings ($88.87 million), and Veralto Corporation ($935,000), according to Watchlist News.
The moves show Cullen Capital's appetite for diversified holdings across pharmaceuticals, consumer goods, and industrial sectors. These Q2 filings reveal how major institutional investors continue building stakes in established companies even as broader market conditions shift.
Axalta Draws Analyst and Institutional Attention
Axalta Coating Systems has become a focal point for institutional money. About 98.28% of the company's stock is held by institutional investors, Watchlist News reported, making Cullen Capital's new $3.34 million position part of a much larger trend.
The move sparked fresh analyst interest. Mizuho raised its price target on Axalta following Cullen Capital's Q2 activity, signaling renewed confidence in the coatings manufacturer.
Pharmaceutical Giant Draws Continued Hedge Fund Interest
Bristol Myers Squibb attracted Cullen Capital's largest new allocation at $65.25 million for 1,132,367 shares. The pharma company sits in a highly institutionalized environment where hedge funds and institutions own 76.41% of outstanding stock, according to Watchlist News.
This concentration of institutional ownership suggests confidence in the company's direction. Cullen Capital's sizable position joins other major investors betting on Bristol Myers' pipeline and market position.
Clorox Dividend Announced Alongside New Stake
Clorox declared a quarterly dividend of $1.25 per share as Cullen Capital built its 10,694-share stake valued at $1.02 million. The record date is set for August 12 with payment on August 28, Watchlist News reported.
The dividend announcement came during earnings season, providing income alongside growth potential. This timing shows how institutional investors like Cullen Capital seek both yield and upside in mature consumer companies.
Veralto CEO Sells While Holding Strong Position
Veralto's CEO Jennifer Honeycutt sold 7,097 shares on July 29 at an average price of $101.52, according to Watchlist News. Despite the sale, Honeycutt retains a substantial position in the industrial measurement company.
Cullen Capital acquired 10,547 shares worth roughly $935,000 in the second quarter. The insider sale alongside institutional buying shows different investor time horizons and valuations for the stock.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
42
Articles
44
Reach
86
Topics
A
AnonymousAuthor
